ANDREW GUGGENHIME - 18 May 2022 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
President and CFO
Signature
Andrew Guggenhime, by /s/ Ron Metzger, Attorney-in-Fact
Issuer symbol
PCVX
Transactions as of
18 May 2022
Transactions value $
-$59,178
Form type
4
Filing time
20 May 2022, 17:01:10 UTC
Previous filing
20 Apr 2022
Next filing
12 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Options Exercise $16.6K +3.1K +7.35% $5.35 45.3K 18 May 2022 Direct F1
transaction PCVX Common Stock Sale -$61.1K -2.52K -5.56% $24.26 42.8K 18 May 2022 Direct F2, F3
transaction PCVX Common Stock Sale -$14.6K -580 -1.36% $25.22 42.2K 18 May 2022 Direct F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Options Exercise $0 -3.1K -0.61% $0.00 503K 18 May 2022 Common Stock 3.1K $5.35 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 1,562 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on May 17, 2022.
F2 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F3 The price reported is a weighted-average price. The shares were sold at prices ranging from $24.04 to $24.99. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F4 The price reported is a weighted-average price. The shares were sold at prices ranging from $25.065 to $25.365. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F5 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter.